title: [Recommendations on the use of 5-amino-levulinic acid in surgery of malignant gliomas. Consensus document. The Neuro-oncology Working Group of the Spanish Neurosurgical Society (SENEC)].
abstract: Among the prognostic factors when it comes to patients with high-grade gliomas, we find the radicality of the surgery performed. The limitations of this factor are caused by either the extension of the tumour or its location in an eloquent area. To achieve this goal, in the last few years we have developed several methods that allow us to maximise tumour resection, while always trying to cause the least possible co-morbidity. One of these methods includes the use of 5-amino-levulinic acid (5-ALA) and the development of fluorescence guided surgery. However, optimal performance requires knowledge of the product employed, the mode of administration and precautions to consider. Members of the neuro-oncology work group of the Spanish Neurosurgical Society (SENEC) have prepared this guideline or consensus document for anyone who wishes to become familiar with the use of 5-ALA fluorescence-guided surgery in the management of high-grade gliomas. For those who already utilise this technique, this document can be useful for consultation purposes.
authors.affiliation: Servicio de Neurocirugía, Hospital Universitario Puerta del Mar, Cádiz, España. Electronic address: jlgilsalu@hotmail.com.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Gil-Salú
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Arraez
authors.forename: Juan Antonio
authors.initials: JA
authors.lastname: Barcia
authors.forename: José
authors.initials: J
authors.lastname: Piquer
authors.forename: Angel
authors.initials: A
authors.lastname: Rodríguez de Lope
authors.forename: Gloria
authors.initials: G
authors.lastname: Villalba Martínez
mesh_terms: D000622:Aminolevulinic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001932:Brain Neoplasms / Q000378:metabolism / Q000601:surgery*; D019317:Evidence-Based Medicine; D005128:Eye Diseases / Q000139:chemically induced / Q000517:prevention & control; D005456:Fluorescent Dyes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D005910:Glioma / Q000378:metabolism / Q000601:surgery*; D006801:Humans; D007022:Hypotension / Q000139:chemically induced / Q000517:prevention & control; D008027:Light / Q000009:adverse effects; D008856:Microscopy, Fluorescence / Q000295:instrumentation; D009493:Neurosurgery / Q000379:methods*; D061848:Optical Imaging / Q000295:instrumentation / Q000379:methods*; D010787:Photosensitivity Disorders / Q000139:chemically induced / Q000517:prevention & control; D011300:Preoperative Care; D025321:Surgery, Computer-Assisted / Q000295:instrumentation / Q000379:methods*; D014018:Tissue Distribution
chemical_list: D005456:Fluorescent Dyes; D000622:Aminolevulinic Acid
keywords: 5-amino-levulinic acid; Cirugía; Gliomas de alto grado; High-grade gliomas; Surgery; Ácido 5-aminolevulínico